PMD20 COST-EFFECTIVENESS ANALYSIS OF A NEW INDEX FOR PROSTATE CANCER DETECTION  by Nichol, M.B. et al.
tified between January 1, 2007 and December 31, 2009. The surgical approach was
laparoscopic in 57.3%patients, and open in 42.7%patients.Mean cost per discharge
was significantly higher in open thoracic procedures compared to laparoscopic
procedures, $24,995 vs. $19,238, respectively(p0.001). Patients undergoing laparo-
scopic thoracic procedures had a significantly lower rate of surgical site infections
compared to patientswho underwent open procedures (4.8% vs. 5.8%, respectively,
p0.001). There was a significantly higher rate of blood transfusions with patients
undergoing open surgery compared to patients undergoing laparoscopic proce-
dures (13.2% vs. 6.3%, respectively, p0.001). CONCLUSIONS: Laparoscopic tho-
racic procedureswere associatedwith shorter hospital lengths of stay, lower rate of
surgical site infections, hemorrhage, blood transfusion and mortality rates. The
mean costs for laparoscopic procedures were significantly lower than mean costs
for open procedures. These observations highlight the potential cost advantages of
providing thoracic procedures through laparoscopic techniques as a method to
potentially save increasingly scarce healthcare funds for hospitals.
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OBJECTIVES: Analyze the differential in selected direct costs of a collaborative
structured blood glucose testing intervention in non-insulin treated patients with
type 2 diabetes mellitus (T2DM) when compared to enhanced usual care (active
control group (ACG)). METHODS: Data was derived from the Structured Testing
Program (STeP) - a 1 year, prospective, cluster-randomized, multicenter study that
examined the utility of a collaborative intervention using structured self-monitor-
ing of blood glucose (SMBG) in 483 poorly-controlled (HbA1c 7.5%) T2DM subjects
compared to the ACG. The structured testing group (STG) used the ACCU-CHEK®
360¢a View 3-day profile tool that facilitates collection and interpretation of 7-point
glucose profiles. From a US payer perspective, direct costs of diabetesmedications,
lab HbA1c tests, physician visits, and blood glucose testing strips associated with
STG were compared with ACG using student t-test at a significance level of 5%.
RESULTS: In the intent-to-treat population, STG showed a significantly greater
HbA1c reduction over 12 months than the ACG (-1.2% vs. 0.9%; 	-0.3%; p0.04).
During the study, STG incurred $180.95 mean PPPY (Pay per Patient Year) total
cost for diabetes medications, but -$173.73 mean PPPY for SMBG test strips, -$5.20
mean PPPY for labHbA1c tests, and -$2.15mean PPPY for physician visits compared
to ACG. There was no significant difference in direct costs between STG and ACG
(p 0.9898). CONCLUSIONS: Use of a collaborative structured testing intervention
improved HbA1c in STG without increasing direct cost. The increased STG medi-
cation cost was offset by a decreased use of blood glucose test strips. As previously
reported, STG subjects performed significantly fewer tests/day than ACG subjects
(mean  0.9 vs. 1.2, p0.0003) over the year. Structured testing, from a 1 year US
payer perspective, is an effective and overall cost-neutral tool for management of
non-insulin treated patients with type 2 diabetes.
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OBJECTIVES: Sensor-augmented pump therapy (SAPT) demonstrated a significant
reduction in HbA1c levels in type 1 diabetes patients compared to multiple daily
injections of insulin (MDI) in a recent randomized trial. We analyzed the data on
medical resource use collected within the trial and evaluated the long-term cost-
effectiveness of SAPT versusMDI in adultswith type 1 diabetes from the healthcare
systemperspective.METHODS:Wecombined estimates derived from the trial data
and the medical literature to populate the previously-validated CORE Diabetes
Model, which includes a series of Markov constructs that simulate the progression
of diabetes-related complications. During the 52-week trial period, SAPT patients
were provided insulin pumps and 3-day sensors. Electronic records indicated that
sensors were worn only by patients 65% of the time. The incremental reduction in
mean glycated hemoglobin was 0.6 percentage points in patients randomized to
SAPT relative to MDI. RESULTS: Among the 329 adults (19-70 years), mean age was
41 years andmeanduration of diabeteswas 20 years. Total treatment costs over the
52-week follow-up period were estimated at $10,760 for SAPT patients and $5,072
for MDI patients (2010 US$). Discounted (3% per year) lifetime estimates of direct
medical costs and QALYs were $253,493 and 10.794 for SAPT patients and $167,170
and 10.418 for MDI patients. The corresponding ICER was $229,675 per QALY (95%
CI: 139,071 to 720,865). Sensitivity analyses revealed that evolving technologies
could improve the cost-effectiveness of SAPT. With a 6-day sensor, the ICER de-
creased to $168,104 per QALY. Upon development of a 6-day sensor that requires
only one test strip per replacement for calibration, the ICER would drop to
$72,417/QALY. CONCLUSIONS: Our base-case findings revealed that the current
SAPT technology is not economically attractive. However, with technological ad-
vances currently in process, the cost-effectiveness of the SAPT could significantly
improve.
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OBJECTIVES: To assess the cost-effectiveness of epidermal growth factor receptor
(EGFR) gene mutation testing for guiding the application of gefitinib as first-line
therapy in patients with advanced non-small cell lung cancer (NSCLC) living in
Ontario. METHODS: A decision analytic model was developed to compare EGFR
gene mutation testing strategy versus no testing strategy in patients with ad-
vanced NSCLC. Under the testing strategy, patients tested positive for mutation
would receive gefitinib as first-line therapy. Under no testing strategy, patients
would receive conventional chemotherapy as first-line therapy. Probability vari-
ables were estimated through literature review. Utility variables were estimated
from a multivariate linear regression analysis taking into account of the clinical
responses and side-effects associated with treatment for NSCLC. Cost variables
were based on two Ontario cost studies for NSCLC. Both benefits and costs were
discounted at 5% per annum. RESULTS: Compared to no testing strategy, the in-
cremental cost-effectiveness ratio for EGFR gene mutation testing was $46,021 per
life year or $81,071 per quality adjusted life year (QALY). The cost-effectiveness of
EGFR gene mutation testing was sensitive to the cost and efficacy of gefitinib. The
budget impact analysis projected that EGFR gene mutation testing would cost On-
tario health care system $4.6M, $7.0M, $7.9M, $8.1M, and $8.1M more a year in the
next five years. CONCLUSIONS: EGFR gene mutation testing would not be cost-
effective in patients with advanced NSCLC in Ontario until willingness-to-pay was
above $81,000 per QALY. The efficacy and cost of gefitinib significantly affected the
cost-effectiveness of EGFR gene mutation testing.
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OBJECTIVES: A new prostate cancer detection index was developed as a combina-
tion of serum prostate-specific antigen (PSA), free PSA, and a PSA precursor form
[-2]proPSA to calculate the probability of prostate cancer and used as a diagnostic
aid for men age 50 years or older with PSA 4-10 ng/mL and nonsuspicious digital
rectal exam. The index has demonstrated improved specificity for detecting pros-
tate cancer over PSA test alone in clinical trials. The current study evaluated the
cost-effectiveness of early prostate cancer detection with the index adding to PSA
compared with PSA test alone from the U.S. societal perspective. METHODS: A
Markov model with probabilistic sensitivity analysis was constructed to estimate
the costs and health state utilities of prostate cancer detection and consequent
treatment for the annual prostate cancer screening of themale fromage 50 through
75 years. The transition probabilities, health state utilities, and prostate cancer
treatment costs were derived from the published literature. The diagnostic perfor-
mance of the index was obtained from a multi-center simulation study of the
index. Diagnostic related costs were obtained from the 2009 Medicare Fee Sched-
ule. Expected costs and effects were discounted at 3%. RESULTS: Over 25 annual
screening cycles, the strategy of the index adding to PSA dominated the PSA test
alone for prostate cancer detection. It was estimated to save $234, with an expected
gain of 0.02 quality adjusted life years (QALYs). The probability of the index test
being cost-effective is approximately 85% at the range of $50,000/QALY to $200,000/
QALY willingness to pay. Model results are most influenced by screening starting
age, discount rate, and biopsy utilization rates. CONCLUSIONS: The index as an aid
adding to PSA test may be an important strategy for prostate cancer detection as
compared to using PSA alone testing.
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OBJECTIVES: To assess the cost-effectiveness of CyberKnife (CK) compared to sur-
gery and radiation therapies for the treatment of localized prostate cancer (PC)
from societal and third party payer perspectives.METHODS: A Markov model was
used to compare treatmentwith CK, intensitymodulated radiation therapy (IMRT),
proton therapy (PT), and surgery, in 60-year-old patients. Themodel reflected both
procedure-relatedmortality and the comparative risks of long-term toxicity among
survivors, defined as adverse events grade 2 on Radiation Therapy Oncology
Group scale occurring at least 12 months following treatment: genitourinary (GU);
gastrointestinal (GI); and/or sexual dysfunction (SD). In the absence of evidence on
comparative effectiveness we assumed that long-term disease control andmortal-
ity would not differ across treatments. Toxicity probabilities were derived using
meta-analytical techniques. Utilities for adverse events were derived from a pub-
lished survey of PC patients using standard gamble technique. Model-projected
expected lifetime costs and quality adjusted life years (QALYs) for each treatment
were used to calculate the incremental cost-effectiveness of CK versus compara-
tors. The societal perspective included productivity costs owing to time spent in
treatment. Extensive sensitivity analyses were conducted. RESULTS: From a pay-
er’s perspective, surgery was least expensive followed by CK, IMRT and PT. How-
ever, CK patients had higher expected QALYs (9.54) than other options (9.08-9.49).
Incremental cost per QALY gained for CK versus surgery was $13,100/QALY. Com-
pared to IMRT and PT, CK was less costly with higher QALYs (dominant). From a
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